F. Baas

Phase I study of BAY 43-9006 (sorafenib), a Raf kinase and VEGFR inhibitor, combined with irinotecan (CPT-11) in advanced solid tumors

B. Schwartz, E. Brendel, K. Mross, 2005 .

Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib.

C. Unger, M. Radtke, E. Brendel, 2007, European journal of cancer.

Phase I Study of the Angiogenesis Inhibitor BIBF 1120 in Patients with Advanced Solid Tumors

R. Kaiser, C. Unger, Jürgen Henning, 2009, Clinical Cancer Research.

A clinical phase I, pharmacokinetic (PK), and pharmacodynamic study of twice daily BIBF 1120 in advanced cancer patients

Jürgen Hennig, Ralph Strecker, J. Hennig, 2005 .

Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors.

B. Schwartz, E. Brendel, D. Voliotis, 2003, International journal of clinical pharmacology and therapeutics.